Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opening Session Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Oct

Today In Oncology

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opening Session Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC

Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer

Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC

Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases

High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery